Consequences of Implantable Device Infection on Patients and the Healthcare System
Both the TYRXTM Neuro Absorbable Antibacterial Envelope and the TYRXTM Cardiac Absorbable Antibacterial Envelope for cardiac implantable electronic devices (CIEDs) are designed to help reduce infection, and they share many of the same features.
Cardiac implant research shows that despite efforts to take precautions and reduce risks, infection after implanting a CIED is a real possibility. When CIED infection does occur, the risk to the patient and the costs to the healthcare system are substantial.1-3
Cardiac infections typically cost the facility an average of ~$52,0004 but may exceed well over $100,000.3
CIED INFECTION AND MORTALITY
Mortality significantly increased following CIED infections. Studies show a ~50% mortality rate at three years in patients who had a CIED infection.1
CIED Infections Are Costly
An infection may cost a facility $52,000 on
CIED infection rates affect Centers for Medicaid and Medicare Services (CMS) reimbursement.4 As of October 1, 2012, the CMS has reduced payments to hospitals when a patient undergoing a CIED procedure acquires an infection during their hospital stay.4
BENEFITS OF TYRX ANTIBACTERIAL ENVELOPES
The TYRX™ Neuro Absorbable Antibacterial Envelope may help reduce infection; studies show a 70% to 100% reduction of infection in high-risk patients in a cardiac application.
Economic Impact of CIED Infection1-3
1
Mittal S et al. Heart Rhythm. 2014;11(4):595-601.
2
Henrikson CA et al. JACC EP.2017;3(10):1158-1167.
3
Sohail MR et al. Arch Intern Med. 2011;171(20):1821-1828.
4
Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services Inpatient Prospective Payment System (IPPS) Final Rule FY13.